Mohammed T. Abou-Saleh

PSYCHOPHARMACOLOGICAL TREATMENT OF ANXIETY 56925. Pomara N, Stanley B, Block R et al. Adverse effects of singletherapeutic doses of diazepam on performance in normal geriatricsubjects: relationships to plasma concentrations. Psychopharmacology1984; 27: 273–81.26. Nikaido AM, Ellinwood EH Jr, Heatherly DG, Dubow D.Differential CNS effects of diazepam in elderly adults. PharmacolBiochem Behav 1987; 27: 273–81.27. Skegg DCG, Richards SM, Doll R et al. Minor tranquilizers and roadaccidents. Br Med J 1979; 1(6168): 917–19.28. Weilburg JB, Sachs G, Falk WE. Triazolam-induced brief episodes ofsecondary mania in a depressed patient. J Clin Psychiat 1987; 48(12):492–3.29. Goodman WK, Charney DS. A case of alprazolam, but notlorazepam, inducing manic symptoms. J Clin Psychiat 1987; 48(3):117–18.30. Gershon S, Eison AS. Anxiolytic profiles. J Clin Psychiat 1983; 44(11, 2): 45–57.31. Sadavoy J, LeClair JK.Treatment of anxiety disorders in late life. CanJ Psychiat 1997; 42(suppl 1): 28–34S.33. Eison AS, Temple DL Jr. Buspirone: review of its pharmacology andcurrent perspectives on its mechanism of action. Am J Med 1986; 80(suppl 3B): 1–9.34. Goa KL, Ward A. Buspirone: a preliminary review of itspharmacologic properties and therapeutic efficacy as an anxiolytic.Drugs 1986; 32: 114–29.35. Napoleillo MJ. An interim multicentre report on 677 anxious geriatricout-patients treated with buspirone. Br J Clin Pract 1986; 40: 71–3.36. Singh AN, Beer M. A dose range finding study of buspirone ingeriatric patients with symptoms of anxiety. J Clin Psychopharmacol1988; 8: 67–8.37. Robinson D, Napoliello MJ, Schenk J. The safety and usefulness ofbuspirone as an anxiolytic drug in elderly versus younger patients.Clin Ther 1988; 10(6): 740–6.38. Bohm C, Robinson DS, Gammans RE et al. Buspirone therapy inanxious elderly patients: a controlled clinical trial. J ClinPsychopharmacol 1990; 10(suppl 3): 47–51S.39. Sheehan DV, Raj AB, Sheehan KH, Soto S. Is buspirone effective forpanic disorder? J Clin Psychopharmacol 1990; 10(1): 3–11.40. Schweizer E, Rickels K, Lucki I. Resistance to the anti-anxiety effectof buspirone inpatients with a history of benzodiazepine use. N Engl JMed 1986; 314: 719–20.41. Banazak DA. Anxiety disorders in elderly patients. J Am Board FamPract 1997; 10(4): 280–9.42. Steinberg JR. Anxiety in elderly patients. A comparison of azapironesand benzodiazepines. Drugs Aging 1994; 5(5): 335–45.43. Rifken A, Klein DF, Dillon D, Levitt M. Blockade by imipramine ordesipramine of panic induced by sodium lactate. Am J Psychiat 1981;138: 676–7.44. Crook T. Diagnosis and treatment of mixed anxiety–depression in theelderly. J Clin Psychiat 1982; 43(9): 35–43.45. Hershey LA, Kim KY. Diagnosis and treatment of anxiety in theelderly. Rational Drug Ther 1988; 22(3): 1–6.46. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects ofalprazolam and imipramine in generalized anxiety disorder: somaticvs. psychic symptoms. J Clin Psychiatry 1988; 49: 293–301.47. Rickels K, Downing R, Schweizer E et al. Antidepressants for thetreatment of generalized anxiety disorder: a placebo-controlledcomparison of imipramine, trazodone, and diazepam. Arch GenPsychiat 1993; 50: 884–95.48. Georgotas A, McCue RE, Hapworth W et al. Comparative efficacyand safety of MAOIs vs. TCAs in treating depression in the elderly.Biol Psychiat 1986; 21: 1155–66.49. Fyer AJ, Sandberg D. Pharmacologic treatment of panic disorder. InFrancis AJ, Hales RE, eds, Review of Psychiatry. Washington, DC:American Psychiatric Press, 1988; 88–120.50. Tiller JW, Bouwer C, Behnke K. Moclobemide for anxiety disorders:a focus on moclobemide for panic disorder. Int Clin Psychopharmacol1997; 12(suppl 6): S27–30.51. Versiani M, Amrein R, Montgomery SA. Social phobia: long-termtreatment outcome and prediction of response—a moclobemidestudy. Int Clin Psychopharmacol 1997; 12(5): 239–54.52. Feighner JP, Boyer WF, Meredith CH, Hendrickson G. An overviewof fluoxetine in geriatric depression. Br J Psychiat 1988; 3: 105–8.53. Perse TL, Greist JH, Jefferson JW, Rosenfield R, Dar R.Fluvoxamine treatment of obsessive-compulsive disorder. Am JPsychiat 1987; 144: 1543–8.54. Katzelnick DJ, Greist JH, Jefferson JW, Kobak KA. Sertraline insocial phobia: a controlled pilot study. Neuropsychopharmacol 1994;10(suppl 35): 260S.55. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1994;31: 767–71.56. Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy insocial phobia. J Clin Psychiat 1993; 54: 27–32.57. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacologicaltreatment of social phobia: A double-blind placebo controlled studywith fluvoxamine. Psychopharmacology Berl 1994; 115: 128–34.58. Smith SL, Sherrill KA, Colenda CC. Assessing and treating anxiety inelderly persons. Psychiat Serv 1995; 46(1): 36–42.59. van Laar MW, van Willigenburg AP, Volkerts ER. Acute andsubchronic effects of nefazodone and imipramine on highway driving,cognitive functions, and daytime sleepiness in healthy adult andelderly subjects. J Clin Psychopharmacol 1995; 15: 30–40.60. Fawcett J, Marcus RN, Anton SF et al. Response of anxiety andagitation symptoms during nefazodone treatment of majordepression. J Clin Psychiatry 1995; 37: 713–38.61. Silverstone PH, Ravindran A. Once-daily venlafaxine extendedrelease (XR) compared with fluoxetine in outpatients withdepression and anxiety. Venlafaxine XR 360 study group. J ClinPsychiat 1999; 60(1): 22–8.62. Kasper S, Przschek-Rieder N, Tauscher J, Wolf R. A risk–benefitassessment of mirtazapine in the treatment of depression. Drug Safety1997; 17(4): 251–64.63. Chou JCY, Sussman N. Neuroleptics in anxiety. Psychiat Ann 1988;18(3): 172–5.64. Peet M. The treatment of anxiety with b-blocking drugs. PostgradMed J 1988; 64(suppl 2): 45–9.65. Greendyke R, Kanter D, Schuster D et al. Propranolol treatment ofassaultive patients with organic brain disease: a double-blind crossover,placebo-controlled study. J Nerv Ment Dis 1986; 174: 290–4.66. Rickels K. Non-benzodiazepine anxiolytics: clinical usefulness. J ClinPsychiat 1983; 44(11): 38–43.67. Blazer DG. Generalized anxiety disorder and panic disorder in theelderly: a review. Harvard Rev Psychiat 1997; 5(1): 18–27.68. Petrie WM, Ban TA. Propranolol in organic agitation. Lancet 1981;1: 324.69. Pohl R, Balon R, Yeragani VK, Gershon S. Serotoninergicanxiolytics in the treatment of panic disorder: A controlled studywith buspirone. Psychopathology 1989; 22(suppl 1): 60–7.70. Sheikh JI, Salzman C. Anxiety in the elderly: course and treatment.Psychiat Clin N Am 1995; 18(4): 871–83.71. Steinberg J. Prescription drug impairment in the elderly. Drug Ther1994; 199(suppl): 83–100S.72. Weiss KJ. Optimal management of anxiety in older patients. DrugsAging 1996; 9(3): 191–201.